Executive Director, Clinical Biomarkers and Companion Diagnostics

Stephen Huang, Ph.D., serves as Executive Director, Clinical Biomarkers and Companion Diagnostics for Avenzo Therapeutics. Dr. Huang has more than 20 years of drug development experience, most recently serving as Executive Director, Translational Sciences, at Artiva Biotherapeutics.

Prior to joining Artiva, he was the Executive Director, Clinical Biomarkers and Companion Diagnostics at Turning Point Therapeutics, which was acquired by Bristol Myers Squibb in 2022. At Turning Point Therapeutics/BMS, he led the clinical biomarkers and companion diagnostics function to support the global development of multiple clinical stage programs. Prior to Turning Point Therapeutics, he held translational medicine and companion diagnostics roles of increasing responsibility at Pfizer (crizotinib, lorlatinib and palbociclib), Abbvie (Teliso-V), Exelixis (Cabozantinib) to support early and late stage clinical development including reverse translational approach from bedside to bench of next generation cell cycle inhibitor development.

Dr. Huang received his Ph.D. in Molecular and Cellular Biochemistry from Loyola University of Chicago, and a B.S. in Biochemistry from Sun Yat-sen University in China.